A 62-year-old man with acute leukemia and prolonged neutropenia develops invasive aspergillosis. Which feature best distinguishes voriconazole from itraconazole in the management of this patient?

Explanation

## Voriconazole vs. Itraconazole: Discriminating Features in Invasive Aspergillosis ### Clinical Context Invasive aspergillosis in neutropenic patients requires an antifungal with excellent **lung penetration** and **bioavailability** to achieve therapeutic levels at the site of infection. ### Voriconazole **Key Point:** Second-generation triazole with superior pharmacokinetics for invasive mold infections. - Excellent oral bioavailability (>90%) - Superior lung tissue penetration (concentrations exceed serum levels) - Achieves therapeutic CNS levels (important for aspergillal meningitis) - Preferred agent for invasive aspergillosis (FDA-approved, guideline-recommended) ### Itraconazole **Key Point:** First-generation triazole with limited bioavailability and penetration. - Variable and poor oral bioavailability (requires acidic pH; absorption unpredictable) - Poor CNS penetration - Adequate for superficial infections and prophylaxis - **Not suitable** as monotherapy for invasive aspergillosis ### Comparative Table | Feature | Voriconazole | Itraconazole | | --- | --- | --- | | **Oral bioavailability** | >90% (reliable) | 20–50% (variable, pH-dependent) | | **Lung penetration** | Excellent | Moderate | | **CNS penetration** | Good | Poor | | **Aspergillosis coverage** | Excellent (DOC for invasive) | Inadequate as monotherapy | | **Drug interactions** | Moderate (CYP3A4 inhibitor) | High (strong CYP3A4 inhibitor) | | **Adverse effects** | Visual disturbances (transient), hepatotoxicity | Hepatotoxicity, negative inotropic effect | **High-Yield:** Voriconazole is the **standard of care** for invasive aspergillosis in neutropenic patients because of superior bioavailability and tissue penetration. Itraconazole is relegated to prophylaxis and superficial infections. **Mnemonic:** **VORI-BETTER** — Voriconazole: Oral bioavailability, Respiratory (lung) penetration, Invasive aspergillosis treatment. **Clinical Pearl:** In this neutropenic patient with invasive aspergillosis, voriconazole IV followed by oral switch (once stable) is the guideline-recommended approach. Itraconazole would be inadequate and place the patient at risk of treatment failure. [cite:Harrison 21e Ch 207]